S&P 500   3,108.49 (+0.00%)
DOW   27,820.71 (0.00%)
QQQ   202.04 (-0.06%)
CGC   19.88 (+12.70%)
BABA   184.56 (+1.21%)
T   37.53 (+0.94%)
F   8.72 (-0.11%)
PRI   130.92 (-0.46%)
BAC   32.93 (+0.73%)
DIS   146.76 (-0.12%)
S&P 500   3,108.49 (+0.00%)
DOW   27,820.71 (0.00%)
QQQ   202.04 (-0.06%)
CGC   19.88 (+12.70%)
BABA   184.56 (+1.21%)
T   37.53 (+0.94%)
F   8.72 (-0.11%)
PRI   130.92 (-0.46%)
BAC   32.93 (+0.73%)
DIS   146.76 (-0.12%)
S&P 500   3,108.49 (+0.00%)
DOW   27,820.71 (0.00%)
QQQ   202.04 (-0.06%)
CGC   19.88 (+12.70%)
BABA   184.56 (+1.21%)
T   37.53 (+0.94%)
F   8.72 (-0.11%)
PRI   130.92 (-0.46%)
BAC   32.93 (+0.73%)
DIS   146.76 (-0.12%)
S&P 500   3,108.49 (+0.00%)
DOW   27,820.71 (0.00%)
QQQ   202.04 (-0.06%)
CGC   19.88 (+12.70%)
BABA   184.56 (+1.21%)
T   37.53 (+0.94%)
F   8.72 (-0.11%)
PRI   130.92 (-0.46%)
BAC   32.93 (+0.73%)
DIS   146.76 (-0.12%)
Log in

Mallinckrodt Stock Price, Forecast & Analysis (NYSE:MNK)

$3.10
+0.10 (+3.33 %)
(As of 11/21/2019 02:38 PM ET)
Today's Range
$2.94
Now: $3.10
$3.15
50-Day Range
$2.08
MA: $2.82
$3.85
52-Week Range
$1.43
Now: $3.10
$28.66
Volume198,107 shs
Average Volume5.03 million shs
Market Capitalization$260.69 million
P/E Ratio0.39
Dividend YieldN/A
Beta2.53
Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone44-0-17-8463-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.22 billion
Cash Flow$19.38 per share
Book Value$34.66 per share

Profitability

Net Income$-3,607,000,000.00
Net Margins-111.44%

Miscellaneous

Employees3,700
Market Cap$260.69 million
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive MNK News and Ratings via Email

Sign-up to receive the latest news and ratings for MNK and its competitors with MarketBeat's FREE daily newsletter.


Mallinckrodt (NYSE:MNK) Frequently Asked Questions

What is Mallinckrodt's stock symbol?

Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."

How were Mallinckrodt's earnings last quarter?

Mallinckrodt PLC (NYSE:MNK) announced its quarterly earnings results on Tuesday, November, 5th. The company reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.98 by $0.09. The business had revenue of $743.70 million for the quarter, compared to the consensus estimate of $770.56 million. Mallinckrodt had a positive return on equity of 24.36% and a negative net margin of 111.44%. The business's revenue was down 7.0% on a year-over-year basis. During the same quarter last year, the business posted $2.10 EPS. View Mallinckrodt's Earnings History.

When is Mallinckrodt's next earnings date?

Mallinckrodt is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Mallinckrodt.

What price target have analysts set for MNK?

15 analysts have issued 12-month price objectives for Mallinckrodt's stock. Their forecasts range from $2.00 to $22.00. On average, they expect Mallinckrodt's stock price to reach $9.47 in the next year. This suggests a possible upside of 205.4% from the stock's current price. View Analyst Price Targets for Mallinckrodt.

What is the consensus analysts' recommendation for Mallinckrodt?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mallinckrodt in the last year. There are currently 1 sell rating, 11 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Mallinckrodt.

Has Mallinckrodt been receiving favorable news coverage?

Press coverage about MNK stock has trended positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Mallinckrodt earned a news sentiment score of 3.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Mallinckrodt.

Who are some of Mallinckrodt's key competitors?

What other stocks do shareholders of Mallinckrodt own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mallinckrodt investors own include Micron Technology (MU), Gilead Sciences (GILD), Bausch Health Companies (BHC), Gerdau (GGB), Teva Pharmaceutical Industries (TEVA), Celgene (CELG), Skyworks Solutions (SWKS), Endo International (ENDP), Alibaba Group (BABA) and AT&T (T).

Who are Mallinckrodt's key executives?

Mallinckrodt's management team includes the folowing people:
  • Mr. Mark Christopher Trudeau, Pres, CEO & Director (Age 58)
  • Dr. Frank Scholz, Exec. VP and Chief Operations & Digital Innovation Officer (Age 50)
  • Mr. Matthew K. Harbaugh, Exec. VP & Pres of Specialty Generics (Age 49)
  • Mr. Hugh M. O'Neill, Exec. VP & Chief Commercial Officer (Age 56)
  • Mr. Bryan M. Reasons, Chief Financial Officer (Age 52)

Who are Mallinckrodt's major shareholders?

Mallinckrodt's stock is owned by a number of of institutional and retail investors. Top institutional investors include Creative Planning (0.44%), SG Americas Securities LLC (0.34%), Great West Life Assurance Co. Can (0.30%), Strs Ohio (0.28%), First Trust Advisors LP (0.23%) and California Public Employees Retirement System (0.17%). Company insiders that own Mallinckrodt stock include Bryan M Reasons, Dr Kneeland Youngblood, James E Flynn and Mark Trudeau. View Institutional Ownership Trends for Mallinckrodt.

Which institutional investors are selling Mallinckrodt stock?

MNK stock was sold by a variety of institutional investors in the last quarter, including Rhumbline Advisers, Eqis Capital Management Inc., Commerzbank Aktiengesellschaft FI and Hancock Whitney Corp. View Insider Buying and Selling for Mallinckrodt.

Which institutional investors are buying Mallinckrodt stock?

MNK stock was acquired by a variety of institutional investors in the last quarter, including Creative Planning, First Trust Advisors LP, Strs Ohio, SG Americas Securities LLC, Tibra Equities Europe Ltd, Great West Life Assurance Co. Can, Meeder Asset Management Inc. and Lincoln Capital Corp. Company insiders that have bought Mallinckrodt stock in the last two years include Bryan M Reasons, Dr Kneeland Youngblood and Mark Trudeau. View Insider Buying and Selling for Mallinckrodt.

How do I buy shares of Mallinckrodt?

Shares of MNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Mallinckrodt's stock price today?

One share of MNK stock can currently be purchased for approximately $3.10.

How big of a company is Mallinckrodt?

Mallinckrodt has a market capitalization of $260.69 million and generates $3.22 billion in revenue each year. The company earns $-3,607,000,000.00 in net income (profit) each year or $8.01 on an earnings per share basis. Mallinckrodt employs 3,700 workers across the globe.View Additional Information About Mallinckrodt.

What is Mallinckrodt's official website?

The official website for Mallinckrodt is http://www.mallinckrodt.com/.

How can I contact Mallinckrodt?

Mallinckrodt's mailing address is 3 LOTUS PARK THE CAUSEWAY STAINES-UPON-THAMES, SURREY X0, TW18 3AG. The company can be reached via phone at 44-0-17-8463-6700 or via email at [email protected]


MarketBeat Community Rating for Mallinckrodt (NYSE MNK)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  861 (Vote Outperform)
Underperform Votes:  563 (Vote Underperform)
Total Votes:  1,424
MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt and other stocks. Vote "Outperform" if you believe MNK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel